Pharmaceutical

DF-4101 by AbbVie for Renal Cell Carcinoma: Likelihood of Approval

DF-4101 is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma.

Apr 21, 2024 - 00:00
DF-4101 is under clinical development by AbbVie and currently in Phase I for Renal Cell Carcinoma.
Read the original article

Tags:

Previous Article

DF-4101 by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Next Article

Neumora Schizophrenia Therapy on Hold After Rabbits Face Convulsions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: BIO selects rare disease advocate, biotech executive John Crowley as new CEO

STAT+: BIO selects rare disease advocate, biotech execu...

Dec 5, 2023

Sanofi completes the $1.7bn acquisition of Inhibrx

Sanofi completes the $1.7bn acquisition of Inhibrx

May 31, 2024

STAT+: FDA advisory panel to debate contentious data on Medtronic’s high blood pressure device

STAT+: FDA advisory panel to debate contentious data on...

Aug 23, 2023